| Date | Title | Description | |
|---|---|---|---|
| 16 Feb 2022 | On business and financial situation | Moderna and ROVI announced that they expand their long-term collaboration for the manufacture of mRNA medicines over the next ten years | Download |
| 03 Nov 2021 | On buy-back programmes | The Company reports the commencement, effective as of today, 3 November 2021, of a share buyback program. | Download |
| 16 Jul 2021 | On Corporate Governance | ROVI announces the appointment of Juan López-Belmonte Encina as Chairman of the Company | Download |
| 22 Jun 2021 | On significant placements in financial instruments | Bestinver announces the beginning of an accelerated book build process of up to a 3% of the share capital of Laboratorios Rovi, S.A. | Download |
| 22 Jun 2021 | On significant placements in financial instruments | Hereby inform of the completion of the private placement package. The amount of the Placement amounted to a total of 87.88 million euros, being the unit selling price of 52.25 euros per share. | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 09 Jan 2023 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the fourth quarter of 2022 | Download |
| 15 Dec 2022 | On Corporate Governance | The Company informs about changes in the Board of Directors and the creation of an Advisory Committee. | Download |
| 04 Oct 2022 | On business and financial situation | The Company informs that it has signed a joint venture agreement with Càrniques Ceirà and Grupo Costa to construct a plant for the production of compounds of high technological value. | Download |
| 03 Oct 2022 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the third quarter of 2022 | Download |
| 29 Jul 2022 | Other relevant información | On 26 July 2022 the public deed relating to the Company’s share capital decrease was registered with the Commercial Registry of Madrid. | Download |